The Front Line in Pharma Is No Longer the Drug: It's the Patient Journey
- SAKS Access Team
- 4 days ago
- 2 min read
The pharmaceutical industry's next competitive battleground may be outside of the laboratory. Increasingly, it is looking like the patient experience. As specialty therapies become more sophisticated, reimbursement grows more complex, and consumers expect healthcare to mirror the convenience of other digital services, pharmaceutical companies are reimagining patient support programs (PSPs) from back-office assistance into strategic, technology-enabled ecosystems designed to help patients start and stay on therapy.
Access to medicines has become a significant challenge for manufacturers. Benefit verification, prior authorization, high out-of-pocket costs, and fragmented health records can delay treatment for weeks, particularly for patients managing chronic or rare diseases. Industry leaders increasingly view these barriers as critical moments that determine whether a patient ultimately receives timely care. We were glad to see our perspective on PSPs reinforced during a recent roundtable discussion about the future of PSPs sponsored by IQVIA, where convergence of policy change, consumer expectations, artificial intelligence (AI), and growing payer complexity was discussed as fundamentally reshaping PSPs and requiring a more personalized, integrated approach to care.
Technology is emerging as a powerful enabler of this shift. Rather than replacing human case managers, AI is increasingly being deployed to automate benefits verification, accelerate prior authorization, and identify patients at risk of abandoning therapy. The objective is a "high-tech, high-touch" model in which automation removes administrative friction while trained support specialists focus on complex clinical and emotional tasks. This approach reflects a growing recognition that efficiency alone does not improve adherence; patients still need guidance when navigating an increasingly complicated healthcare system.
At the same time, data quality has become a strategic imperative. Many healthcare organizations still continue to struggle with fragmented patient records spread across providers, pharmacies, and health plans. In a recent report, Verato argues that resolving these disconnected identities through enterprise master patient index technologies enables organizations to create a more complete, accurate view of each patient, reducing duplicate records while supporting more coordinated and personalized engagement across the care continuum. As PSPs become more digitally connected, accurate identity management is becoming foundational to delivering seamless experiences.
Affordability remains a significant challenge for patients. In their 2026 survey, Guidehouse found that 80% of pharmaceutical manufacturers offer copay assistance, making it the most common patient support service, while executives identified payer restrictions, reimbursement complexity, and copay accumulator and maximizer programs among their greatest operational obstacles. Many pharma companies are also reconsidering their operating models, blending internal capabilities with external service partners as they seek greater control over patient data and the overall treatment journey.
Together, these developments point toward a new definition of patient support. The future is no longer measured simply by how many patients enroll, but by whether those PSPs reduce friction, personalize engagement, improve affordability, and help patients start and stay on treatment. For pharmaceutical companies, the prescription may begin with scientific innovation, but sustained success increasingly depends on delivering an experience that is as coordinated as the therapy itself. Here at SAKS Health, providing our clients with expertise and experience in PSPs, patient experience, and market access helps us partner with them to provide Better Healthcare Tomorrow™.
Comments